GW Medical Technologies' New Blood Test for Alzheimer's Disease Seeks Future Test...

PHOENIX -- GW Medical Technologies LLC, the worldwide technology provider of the blood test for Alzheimer's disease (AD) known as the LymPro(TM) Test, announces a nationwide online registration of Alzheimer's patients, caregivers and physicians who want to become involved in upcoming

Those individuals who are interested in participating in future clinical studies can register by going to the company Web site at www.GWmedtech.com. The online registration takes less than one minute to complete. As new clinical studies are launched, those who sign up as interested parties will be contacted first with complete study details and requirements. These studies will be part of the FDA Pre-market Approval (PMA) process for the LymPro Test, which the company is planning to submit to the FDA within the near future.

Additionally, the Web site includes a confidential survey for AD patients, caregivers and physicians to express their attitudes and opinions about the current diagnostic process for Alzheimer's disease. The survey responses will be used to create educational programs explaining how the LymPro Test works and the benefits it provides.

"Bringing this diagnostic blood test for Alzheimer's to market as soon as possible is critical to accelerating treatment options and improving quality of life for thousands of patients and their families who are enduring the current lengthy diagnostic process," said William Gartner, CEO and president of GW Medical Technologies LLC.

The company is in the final phase of its retrospective "blind" pilot study with samples from healthy participants, those with Alzheimer's disease, as well as those with other forms of dementia. This study has been designed to enhance the method prior to undertaking final FDA clinical studies.

About the LymPro Test

Developed by a major European research university, the initial clinical study for the LymPro Test demonstrated high positive correlation with clinical diagnosis and the potential to diagnose Alzheimer's disease before the appearance of clinical symptoms.

The LymPro Test recognizes and quantifies changes in cellular functions in blood samples that are indicative with Alzheimer's disease. These very specific protein expressions on the cell surface allow us to evaluate and differentiate between Alzheimer's disease, other dementias and healthy individuals.

About GW Medical Technologies LLC

GW Medical Technologies LLC is a translational in-vitro diagnostic company focused on the diagnosis of Alzheimer's disease. The company is poised to bring the LymPro Test to market as fast as possible with both U.S. and global approvals. Founded by Gartner and Everett G. Warren, chairman, GW Medical Technologies is located at 1440 E. Missouri Ave., Suite 225, Phoenix, AZ 85014. For more information about the company and the LymPro Test, visit www.GWmedtech.com or call 602-265-7862.